Literature DB >> 29357093

Atrial fibrillation diagnosed by a medical checkup is associated with a poor outcome of catheter ablation.

Ryohsuke Narui1, Teiichi Yamane2, Michifumi Tokuda2, Hirotsugu Ikewaki2, Eri Okajima2, Hidenori Sato2, Hirotsuna Oseto2, Ryota Isogai2, Kenichi Tokutake2, Kenichi Yokoyama2, Mika Kato2, Keiichi Ito2, Shin-Ichi Tanigawa2, Seigo Yamashita2, Keiichi Inada2, Seiichiro Matsuo2, Satoru Miyanaga2, Kenichi Sugimoto2, Michihiro Yoshimura2.   

Abstract

Atrial fibrillation (AF), especially asymptomatic cases, is often detected by medical checkups. We investigated the outcome of AF ablation in cases detected by medical checkups. We reviewed the data of 735 patients with AF (56 ± 10 years, paroxysmal: 441 patients) who underwent initial catheter ablation. All patients were divided into two groups based on their AF being diagnosed either by a medical checkup (group M) or not (group NM). AF was diagnosed by medical checkups in 263 (36%) patients. In Group M, the age was younger, time from the diagnosis to ablation shorter, left atrium dimension larger, and left ventricular ejection fraction lower than in Group NM. Male gender, persistent AF, and asymptomatic AF were more frequently seen in Group M than in Group NM. A mean of 13 ± 11 months after the initial ablation procedure, AF recurrence was more frequently observed in group M compared to group NM (P = 0.018). While the AF recurrence rate was similar in both groups in persistent AF patients (P = 0.87), it was more frequently observed in Group M than in Group NM in paroxysmal AF patients (P = 0.005). AF diagnosed by medical checkups was often associated with a worse outcome of catheter ablation, especially in paroxysmal AF patients.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Medical checkup; Outcome

Mesh:

Year:  2018        PMID: 29357093     DOI: 10.1007/s00380-017-1115-z

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  18 in total

1.  Prospective randomized comparison of a steerable versus a non-steerable sheath for typical atrial flutter ablation.

Authors:  Seiichiro Matsuo; Teiichi Yamane; Michifumi Tokuda; Taro Date; Mika Hioki; Ryohsuke Narui; Keiichi Ito; Seigo Yamashita; Yoshiyuki Hama; Tokiko Nakane; Keiichi Inada; Kenri Shibayama; Satoru Miyanaga; Hiroshi Yoshida; Hidekazu Miyazaki; Kunihiko Abe; Ken-ichi Sugimoto; Ikuo Taniguchi; Michihiro Yoshimura
Journal:  Europace       Date:  2010-01-17       Impact factor: 5.214

2.  Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study.

Authors:  Mélèze Hocini; Pierre Jaïs; Prashanthan Sanders; Yoshihide Takahashi; Martin Rotter; Thomas Rostock; Li-Fern Hsu; Frédéric Sacher; Sylvain Reuter; Jacques Clémenty; Michel Haïssaguerre
Journal:  Circulation       Date:  2005-12-13       Impact factor: 29.690

3.  Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of follow up?

Authors:  Fiorenzo Gaita; Marco Scaglione; Alberto Battaglia; Mario Matta; Cristina Gallo; Michela Galatà; Domenico Caponi; Paolo Di Donna; Matteo Anselmino
Journal:  Europace       Date:  2018-03-01       Impact factor: 5.214

4.  Freedom from paroxysmal atrial fibrillation after successful pulmonary vein isolation with pulmonary vein ablation catheter-phased radiofrequency energy: 2-year follow-up and predictors of failure.

Authors:  Anton A W Mulder; Maurits C E F Wijffels; Eric F D Wever; Lucas V A Boersma
Journal:  Europace       Date:  2012-02-15       Impact factor: 5.214

5.  Dormant pulmonary vein conduction induced by adenosine in patients with atrial fibrillation who underwent catheter ablation.

Authors:  Seiichiro Matsuo; Teiichi Yamane; Taro Date; Nicolas Lellouche; Ken-Ichi Tokutake; Mika Hioki; Keiichi Ito; Ryohsuke Narui; Shin-Ichi Tanigawa; Tokiko Nakane; Michifumi Tokuda; Seigo Yamashita; Yasuko Aramaki; Keiichi Inada; Kenri Shibayama; Satoru Miyanaga; Hiroshi Yoshida; Hidekazu Miyazaki; Kunihiko Abe; Ken-Ichi Sugimoto; Ikuo Taniguchi; Michihiro Yoshimura
Journal:  Am Heart J       Date:  2011-01       Impact factor: 4.749

6.  Repeated provocation of time- and ATP-induced early pulmonary vein reconnections after pulmonary vein isolation: eliminating paroxysmal atrial fibrillation in a single procedure.

Authors:  Teiichi Yamane; Seiichiro Matsuo; Taro Date; Nicolas Lellouche; Mika Hioki; Ryosuke Narui; Keiichi Ito; Shin-ichi Tanigawa; Seigo Yamashita; Michifumi Tokuda; Hiroshi Yoshida; Keiichi Inada; Kenri Shibayama; Satoru Miyanaga; Hidekazu Miyazaki; Kunihiko Abe; Ken-ichi Sugimoto; Michihiro Yoshimura
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-08-13

7.  Technique and results of linear ablation at the mitral isthmus.

Authors:  Pierre Jaïs; Mélèze Hocini; Li-Fern Hsu; Prashanthan Sanders; Christophe Scavee; Rukshen Weerasooriya; Laurent Macle; Florence Raybaud; Stéphane Garrigue; Dipen C Shah; Philippe Le Metayer; Jacques Clémenty; Michel Haïssaguerre
Journal:  Circulation       Date:  2004-11-01       Impact factor: 29.690

8.  Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes.

Authors:  T Jared Bunch; Heidi T May; Tami L Bair; David L Johnson; J Peter Weiss; Brian G Crandall; Jeffrey S Osborn; Jeffrey L Anderson; J Brent Muhlestein; Donald L Lappe; John D Day
Journal:  Heart Rhythm       Date:  2013-05-20       Impact factor: 6.343

9.  Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study.

Authors:  Takeshi Kato; Takeshi Yamashita; Kouichi Sagara; Hiroyuki Iinuma; Long-Tai Fu
Journal:  Circ J       Date:  2004-06       Impact factor: 2.993

10.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; Deirdre A M van der Kuip; Albert Hofman; Jan A Kors; Gerard van Herpen; Bruno H Ch Stricker; Theo Stijnen; Gregory Y H Lip; Jacqueline C M Witteman
Journal:  Eur Heart J       Date:  2006-03-09       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.